Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis.

ABSTRACT:

Background

Cardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addressed. The aim of this study was to assess the correlation between risk of CVEs and AIs in patients with breast cancer.

Methods

Included studies were obtained from the databases of Embase, Pubmed, Cochrane Library, Clinical Trials.gov, and reference lists. The main outcome measures were overall incidence, odds ratios (ORs), and 95% confidence intervals (CIs). Furthermore, the association and the risk differences among different tumor types, AIs,ages,or treatment regimens were conducted. Fixed-effect or random-effect models were applied in the statistical analys

SUBMITTER: He Y 

PROVIDER: S-EPMC6820915 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature